Andy Forreryd1, Joshua Schmidt1, Robin Gradin1, Florence Burleson, Helge Gehrke3, Henrik Johansson1. 1SenzaGen AB, Lund, Sweden. 2Burleson Research Technologies, Morrisville, NC, USA. 3Eurofins BioPharma Product Testing Munich GmbH, Planegg, Germany. Sensitization of the respiratory tract by sensitizing chemicals may lead to severe bronchoconstriction and asthma-like symptoms with a potentially fatal outcome. However, proactive identification and […]
About Tina Dackemark Lawesson
This author has yet to write their bio.
Meanwhile lets just say that we are proud Tina Dackemark Lawesson contributed a whooping 46 entries.
Join SenzaGen’s free web-based SOT 2020 poster presentation session Don’t miss the opportunity to participate in our web-based conference on the latest news about the GARD™ assays for skin and respiratory sensitization testing. Key takeaways – Comparative study: GARDskin for challenging substances – How to test UVCBs and Mixtures – Formal validation of GARDpotency for […]
Did you miss our popular webinar ‘GARD technology: Genomics and Machine Learning’ last year? Here is a new opportunity to participate in a live webinar presented by GARD experts at SenzaGen followed by a Q&A session. Join us and you’ll learn the principles of the technology platform and get an updated overview of its broad […]
Journal of Proteomics Available online 30 January 2020, 03647. https://doi.org/10.1016/j.jprot.2020.103647 Tim Lindberg, Renato Ivan de Ávila, Kathrin S. Zeller, Fredrik Levander, Dennis Eriksson, Aakash Chawaded, Malin Lindstedt Highlights Pure glyphosate was classified as a non-sensitizer using in vitro assessment. POEA, POEA+glyphosate mixture and formulations were identified as skin sensitizers. MS analysis identified protein groups related […]
Here is an easy guide to how GARD skin and respiratory sensitization in vitro assays can help you through various challenges in your product life cycle. Many of our customers use our assays as an integrated part during their product development phase, for example testing for candidate ingredients, formulations or finished products, including various difficult-to-test […]
We wish you a truly happy holiday season, and we look forward to seeing you again in the new year.
Our CEO presented at Vator Unicorn Summit in Stockholm last week and in the video below you can watch him explaining about SenzaGen’s change from a research organization to one with a strong focus on commercialization. Vator Unicorn Summit, November 27, 2019
In case you missed us at Biostock in Stockholm yesterday, CEO Axel Sjöblad explains SenzaGen’s commercialization and how the rights issue is part of the company’s growth strategy in these video clips. Presentation Biostock Live, Dec 3, 2019 Interview Biostock Live, Dec 3, 2019
Lyssna på SenzaGens VD Axel Sjöblad via klippet nedan – om att ta bolaget från ett forskningsbolag till ett lönsamt kommersiellt bolag. SenzaGen på Småbolagsjakten i Stockholm den 27 november.
Tack alla som kom och lyssnade på VD Axel Sjöblads presentation av SenzaGens skifte från forskningsbolag till kommersiellt bolag och den pågående företrädesemissionen på Stora Aktiedagen i Stockholm den 25 november 2019. Missade du presentationen så kan du se den här: